Dr. David Spigel: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

Article

Dr. David Spigel, Sarah Cannon Cancer Center, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

[powerpress]

Dr. David Spigel: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

Article

David Spigel, Sarah Cannon Cancer Center, reviews how he discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

[powerpress]

Dr. David Spigel: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

Article

Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Dr. David Spigel on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

Article

Dr. David Spigel addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.

[powerpress]

Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do "Reflex Testing"?

Article

Dr. David Spigel, Sarah Cannon Cancer Center, reviews which patients with lung cancer he feels should undergo molecular testing, as well as describing the potential value of immediate, reflex testing for molecular targets.

[powerpress]

Subscribe to Sarah Cannon Cancer Center